SCHEMBL2884800

SCHEMBL2884800

Cc1cccc(C(C)(C)C)c1[N+](=O)[O-]

nearest known ligand 0.67

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 4/20 0.67
ALDH1A1 P00352 3/20 0.67
TSHR P16473 5/20 0.58
GABRA1 P14867 1/20 0.52
GABRB2 P47870 1/20 0.52
SMN1; SMN2 Q16637 2/20 0.46
HSD17B10 Q99714 1/20 0.44
KAT2B Q92831 1/20 0.42
KMT2A Q03164 4/20 0.41
MAPT P10636 3/20 0.41
HPGD P15428 2/20 0.40
CYP3A4 P08684 1/20 0.40
POLB P06746 1/20 0.40
L3MBTL1 Q9Y468 2/20 0.40
MEN1 O00255 2/20 0.39
GALR3 O60755 1/20 0.39
HTT P42858 1/20 0.39
CA2 P00918 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3520821 0.83 ALDH1A1 (0.64) TDP1ALDH1A1TSHRSMN1; SMN2HSD17B10
SCHEMBL10781267 0.83 ALDH1A1 (0.64) TDP1ALDH1A1TSHRGABRA1GABRB2
SCHEMBL5643401 0.82 ALDH1A1 (0.58) TDP1ALDH1A1TSHRGABRA1GABRB2
SCHEMBL5644617 0.81 ALDH1A1 (0.56) TDP1ALDH1A1TSHRGABRA1GABRB2
SCHEMBL7617190 0.81 ALDH1A1 (0.56) TDP1ALDH1A1TSHRGABRA1GABRB2
SCHEMBL635089 0.81 ALDH1A1 (1.00) TDP1ALDH1A1TSHRSMN1; SMN2HSD17B10
SCHEMBL10979000 0.81 TSHR (0.58) TDP1ALDH1A1TSHRSMN1; SMN2HSD17B10
SCHEMBL16959731 0.79 TDP1 (0.44) TDP1ALDH1A1TSHRGABRA1GABRB2
SCHEMBL14200086 0.79 ALDH1A1 (0.44) TDP1ALDH1A1TSHRGABRA1GABRB2
SCHEMBL28521563 0.79 ALDH1A1 (0.95) TDP1ALDH1A1TSHRSMN1; SMN2HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8895497-B2 Cathepsin S inhibitors DCB-USA, LLC (US) 2014-11-25 US disclosed
US-8895580-B2 Quinolinone-pyrazolone M1 receptor positive allosteric modulators MERCK SHARP & DOHME CORP. (US) 2014-11-25 US disclosed
CN-102952112-A Tricyclic guanidine derivatives as sodium-proton exchange inhibitors NICHOLAS PIRAMAL INDIA LTD 2013-03-06 CN disclosed
US-20120196845-A1 QUINOLINONE-PYRAZOLONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS MERCK SHARP & DOHME LLC 2012-08-02 US disclosed
US-8183234-B2 Tricyclic guanidine derivatives as sodium-proton exchange inhibitors PIRAMAL LIFE SCIENCES LIMITED (IN) 2012-05-22 US disclosed
US-20110166141-A1 CATHEPSIN S INHIBITORS DCB-USA, LLC (US) 2011-07-07 US disclosed
US-7834001-B2 N-(10,10-Dioxo-10,11-dihydro-5-oxa-10-lambda*6*-thia-dibenzo[a.d]cycloheptene-8-carbonyl)-guanidine; tumor necrosis factor inhibitors; sodium-proton exchange inhibitors for treatment of organ disorders associated with ischemia and reperfusion, cardiac arrhythmia, cardiac hypertrophy PIRAMAL LIFE SCIENCES LIMITED (IN) 2010-11-16 US disclosed
US-20100267690-A1 TRICYCLIC GUANIDINE DERIVATIVES AS SODIUM-PROTON EXCHANGE INHIBITORS PIRAMAL LIFE SCIENCES LIMITED (IN) 2010-10-21 US disclosed
US-20070299051-A1 Tricyclic Guanidine Derivatives as Sodium-Proton Exchange Inhibitors NICHOLAS PIRAMAL INDIA LIMITED. (IN) 2007-12-27 US disclosed
CN-101076526-A Tricyclic guanidine derivatives as sodium-proton exchange inhibitors NICHOLAS PIRAMAL INDIA LTD (IN) 2007-11-21 CN disclosed
EP-1812420-A1 TRICYCLIC GUANIDINE DERIVATIVES AS SODIUM-PROTON EXCHANGE INHIBITORS Nicholas Piramal India Limited (IN) 2007-08-01 EP disclosed
WO-2006051476-A1 TRICYCLIC GUANIDINE DERIVATIVES AS SODIUM-PROTON EXCHANGE INHIBITORS NICHOLAS PIRAMAL INDIA LIMITED (IN) 2006-05-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100267690-A1 TRICYCLIC GUANIDINE DERIVATIVES AS SODIUM-PROTON EXCHANGE INHIBITORS ATP2A1, ATP2A3, KCNN4 TDP1 2213/4885ALDH1A1 1222/4885TSHR 497/4885
US-20120196845-A1 QUINOLINONE-PYRAZOLONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS CHRM1, OPRL1, CHRNA5 TDP1 2391/4885ALDH1A1 2640/4885TSHR 454/4885
US-20070299051-A1 Tricyclic Guanidine Derivatives as Sodium-Proton Exchange Inhibitors ATP2A1, ATP2A3, KCNN4 TDP1 2213/4885ALDH1A1 1222/4885TSHR 497/4885
US-20110166141-A1 CATHEPSIN S INHIBITORS CTSS, CTSV, CTSB TDP1 2773/4885ALDH1A1 2734/4885TSHR 2574/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.